Tocagen
San Diego, US · Delaware corporation · 1 known investors
Biotech
Founders & leadership
TD
Thomas DarcyExecutive Officer, Director
DB
Dennis BermanExecutive Officer, Director
FH
Faheem HasnainDirector
HG
Harry GruberExecutive Officer, Director
LK
Lori KunkelDirector
DJ
Douglas JollyExecutive Officer
DR
David R. ParkinsonDirector
PS
Paul SchimmelDirector
FM
Franklin M. BergerDirector
Investors · 1
Reported raises · per SEC filings
Form D private placements▶$25MraisedAug 2023 · 27 investors · BiotechnologyRule 506(b)
▶$25MraisedAug 2023 · 27 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Antony RileyExecutive Officer
- Stephen DobersteinDirector
- Scott BrunDirector
- Lawrence EichenfieldDirector
- Hubert ChenExecutive Officer
- Steven KornfeldDirector
- David GryskaDirector
- Barbara FinkDirector
- Donald WilliamsDirector
- Paul WagnerExecutive Officer, Director
- Offering amount
- $25M
- Amount sold
- $25M
- First sale
- Jul 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$10.9MraisedMar 2017 · 107 investors · PharmaceuticalsRule 506(b)
▶$10.9MraisedMar 2017 · 107 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Thomas DarcyExecutive Officer, Director
- Faheem HasnainDirector
- Harry GruberExecutive Officer, Director
- Mark FolettaExecutive Officer
- Douglas JollyExecutive Officer
- David R. ParkinsonDirector
- Franklin M. BergerDirector
- Lori KunkelDirector
- Dennis BermanExecutive Officer, Director
- Martin J DuvallExecutive Officer, Director
- Paul SchimmelDirector
- Offering amount
- $13M
- Amount sold
- $10.9M
- First sale
- Nov 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$46.2MraisedOct 2015 · 250 investors · PharmaceuticalsRule 506(b)
▶$46.2MraisedOct 2015 · 250 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Thomas DarcyExecutive Officer, Director
- Dennis BermanExecutive Officer, Director
- Faheem HasnainDirector
- Harry GruberExecutive Officer, Director
- Lori KunkelDirector
- Douglas JollyExecutive Officer
- David R. ParkinsonDirector
- Paul SchimmelDirector
- Franklin M. BergerDirector
- Offering amount
- $50.4M
- Amount sold
- $46.2M
- Minimum investment
- $10.5K
- Sales commissions
- $14K
- Placement agents
- Newbridge Securities Corporation
- First sale
- May 2013
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 2 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2014 | $224.7K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2012 | $269K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.